WORLD'S FIRST VAPOR CURE BOTTLE-COATING LINE.

被引：0
|
作者：
Schrantz, Joe [1 ]
机构：
[1] Industrial Finishing, Wheaton, IL,, USA, Industrial Finishing, Wheaton, IL, USA
来源：
Industrial finishing Wheaton | 1987年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [31] Real-World Characteristics and Survival Outcomes of Patients with Mantle Cell Lymphoma Treated with Covalent Bruton's Tyrosine Kinase Inhibitors in First-Line
    Sawas, Ahmed
    Wade, Niquelle Brown
    Roose, James
    BLOOD, 2024, 144 : 1655 - 1656
  • [32] The World's First InP 8x8 Monolithic Tunable Optical Router (MOTOR) Operating at 40 Gbps Line Rate per Port
    Nicholes, Steven C.
    Masanovic, Milan L.
    Jevremovic, Biljana
    Lively, Erica
    Coldren, Larry A.
    Blumenthal, Daniel J.
    OFC: 2009 CONFERENCE ON OPTICAL FIBER COMMUNICATION, VOLS 1-5, 2009, : 3078 - +
  • [33] First Line B plus R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real- World Experience
    Kotchetkov, Rouslan
    Susman, David
    Gerard, Lauren M.
    Dimaria, Erica
    Nay, Derek
    Prica, Anca
    BLOOD, 2021, 138
  • [34] REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
    Yarur, Andres
    Bressler, Brian
    Wang, Song
    Adsul, Shashi
    Kamble, Pravin
    Luo, Michelle
    Cook, Erin
    Sajeev, Gautam
    Dieye, Ibou
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2021, 160 (06) : S4 - S4
  • [35] S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
    Shi, Yan
    Han, Quanli
    Yan, Huan
    Lv, Yao
    Yuan, Jing
    Li, Jie
    Guan, Shasha
    Wang, Zhikuan
    Huang, Lei
    Dai, Guanghai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] New dimensions - the world's first OptiConcept LWC on-line unit on stream (Contained from WfP 21/00, p. 1423-1470)
    Johansson, BJ
    WOCHENBLATT FUR PAPIERFABRIKATION, 2000, 128 (23-24): : 1654 - 1659
  • [37] First-line treatment with Bendamustine plus Rituximab for patients with indolent non-Hodgkin's lymphoma or Mantle cell lymphoma: Real-world experience.
    Kotchetkov, Rouslan
    Susman, David
    Gerard, Lauren
    DiMaria, Erica
    Nay, Derek Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study
    Fischer, Aren
    Mac, Stephen
    Freiman, Erica Stivelman
    Marshall, John K.
    Rand, Kim
    Ramos-Goni, Juan M.
    PHARMACOECONOMICS-OPEN, 2024, : 41 - 56
  • [39] Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine plus Rituximab
    Irwin, Debra
    Zhang, Lu
    Wilson, Kathleen
    Hoehn, Gerard
    Szabo, Erika
    Tang, Boxiong
    BLOOD, 2018, 132
  • [40] Comparative effectiveness and safety of ustekinumab versus anti-tumour necrosis Factor agents as first- or second-line biologics in Crohn<acute accent>s disease: a real-world multicentric observational study
    Ferreira, S.
    Parra, R. Serafim
    Sassaki, L. Yukie
    de Mello, M. Kurtz
    Parente, J. M. Luz
    Bafutto, M.
    Penna, F. G. Cancela
    Pinho, L. Penna
    Froes, R. de Sa Brito
    Gasparetti Jr, N. L. Tricarico Gasparetti
    Chebli, L. Andrade
    Alves Jr, A. J. Tiburcio
    Nobrega, F. J. Firmino
    Quaresma, A. Botelho
    Nicollelli, G. Mattioli
    Gasparini, R. Galhardi
    Dutra, R. de Medeiros
    Magro, D. Oliveira
    Camargo, M. Gardere
    Parente, L. Palha Dias
    Feres, O.
    Troncon, L. E. de Almeida
    Kotze, P. G.
    Chebli, J. M. Fonseca
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1637 - i1638
12345